Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
Go back to Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 116.00 -2.52 (2.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $118.52 | 52 Week High | $118.49 | |||
| Open | $118.53 | 52 Week Low | $55.00 | |||
| Day High | $118.93 | P/E | N/A | |||
| Day Low | $115.21 | EPS | $-0.56 | |||
| Volume | 700,579 | |||||
